| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2003;75:1261-1266
© 2003 The Society of Thoracic Surgeons
a Division of Cardiology and Critical Care Medicine, Chicago, Illinois, USA
b Division of Cardiovascular Thoracic Surgery, Chicago, Illinois, USA
c Division of General Academic Pediatrics, Child Health Research Core, Children’s Memorial Institute for Education and Research, Children’s Memorial Hospital and Feinberg School of Medicine at Northwestern University, Chicago, Illinois, USA
Accepted for publication October 18, 2002.
* Address reprint requests to Dr Backer, Division of Cardiovascular Thoracic Surgery, Children’s Memorial Hospital, 2300 Children’s Plaza, m/c 22, Chicago, IL 60614, USA
e-mail: cbacker{at}childrensmemorial.org
BACKGROUND: The use of aprotinin in children undergoing cardiopulmonary bypass is controversial. We hypothesized that aprotinin would reduce blood product use and operative closure time in selected pediatric patients.
METHODS: For a 6-month period starting in October 1999, consecutive cardiopulmonary bypass patients 6 months of age or less (n = 18) or having a repeat sternotomy (n = 18) received aprotinin. Similar consecutive patients from the preceding 6 months served as controls (n = 35 and 41, respectively). Data extracted from medical records included preoperative clinical characteristics, operative and postoperative procedures, and total blood product use.
RESULTS: Patients in the aprotinin and control groups were well matched with regard to preoperative and intraoperative variables. Patients 6 months of age or less who received aprotinin required less operative closure time when compared with controls (median, 93 vs 127 minutes, p = 0.004), and trended toward requiring fewer red blood cell unit exposures (median, three vs five exposures, p = 0.07). Patients undergoing repeat sternotomy who received aprotinin required less operative closure time when compared with controls (mean, 126 vs 159 minutes, p = 0.007), fewer red blood cell unit exposures (median three vs four exposures, p = 0.002), and fewer fresh-frozen plasma unit exposures (median, zero vs one exposure, p = 0.007).
CONCLUSIONS: Aprotinin reduced operative closure time and blood product exposure in pediatric patients undergoing cardiopulmonary bypass who were 6 months of age or less or underwent a repeat sternotomy.
This article has been cited by other articles:
|
|
 |
|
  N. A. Guzzetta, F. M. Evans, E. S. Rosenberg, T. M. Fazlollah, M. J. Baker, E. C. Wilson, A. M. Kaiser, S. R. Tosone, and B. E. Miller The Impact of Aprotinin on Postoperative Renal Dysfunction in Neonates Undergoing Cardiopulmonary Bypass: A Retrospective Analysis Anesth. Analg., February 1, 2009; 108(2): 448 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Backer, A. M. Kelle, R. D. Stewart, S. C. Suresh, F. N. Ali, R. A. Cohn, R. Seshadri, and C. Mavroudis Aprotinin is safe in pediatric patients undergoing cardiac surgery. J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1421 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Mossad, S. Machado, and J. Apostolakis Bleeding following deep hypothermia and circulatory arrest in children. Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 34 - 46. [Abstract] [PDF]
|
|
|
|
|
|
A. Sedrakyan, A. Wu, G. Sedrakyan, M. Diener-West, M. Tranquilli, and J. Elefteriades Aprotinin use in thoracic aortic surgery: Safety and outcomes J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 909 - 917. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
